Resolve Therapeutics Advances Phase 2 Trial for Sjögren's Disease Treatment with RSLV-132 #USA #Miami #Sjögren's_Disease #Resolve_Therapeutics #RSLV-132
@newsen.bsky.social
@newsen.bsky.socialResolve Therapeutics Advances Phase 2 Trial for Sjögren's Disease Treatment with RSLV-132 #USA #Miami #Sjögren's_Disease #Resolve_Therapeutics #RSLV-132
@globalvisibility.bsky.social
@ajpathology.bsky.socialPathogenesis-Driven Advances in Diagnosis and Treatment of #Sjögren Disease. @dgsomucla.bsky.social @mgbresearch.bsky.social
#OpenAccess text: https://ajp.amjpathol.org/article/S0002-9440(26)00231-2/fulltext
@suffolksight.bsky.social#NationalEyeHealthWeek. Dry eye affects one in three of us. Age, screen use, menopause & contact lens use can all increase your risk. Autoimmune disease such as #Sjögren's and complications from ocular surgery are also risk factors. Speak to your local optical practice for advice.
@fredaustralia.bsky.socialToday, our Co-Founder Dr Alexandra Jones attended an event at Charles Sturt University focused on building medical students’ understanding of #Sjögren’s disease. 🧵 1/5
@newsen.bsky.socialSjögren's Syndrome Market Expected to Grow Significantly Between 2026 and 2036 as New Therapies Emerge #USA #Las_Vegas #Telitacicept #Sjögren's_Syndrome #Dazodalibep
@molettini.bsky.socialMorgen, Himmel. ™️ Die jährliche #Sjögren-Kontrolle steht an. Mir erscheint sie ja sinnlos. Seufz.